Genmab
1,765.00 DKK
+1.67 %
Less than 1K followers
GMAB
NASDAQ Copenhagen
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Dividend
Investor consensus
+1.67 %
+0.37 %
-11.19 %
-12.93 %
-4.02 %
+23.47 %
-35.37 %
-20.60 %
+5,075.95 %
Genmab is a pharmaceutical company. The company specializes in the research and development of antibodies, which are mainly used in the treatment of cancer patients with lymphatic leukemia and solid tumors. Research and development are based on the company's own developed technology platform and operations are held on a global level. Genmab was founded in 1999 and is headquartered in Copenhagen, Denmark.
Read moreMarket cap
110.05B DKK
Turnover
41.48M DKK
Revenue
23.65B
EBIT %
28.63 %
P/E
17.91
Dividend yield-%
-
Revenue and EBIT-%
Revenue B
EBIT-% (adj.)
EPS and dividend
EPS (adj.)
Dividend %
Financial calendar
7.5
2026
Interim report Q1'26
6.8
2026
Interim report Q2'26
5.11
2026
Interim report Q3'26
All
Research
Press releases
ShowingAll content types
Major Shareholder Announcement
Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2026
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
